Showing results (291-300 of 419) with videos related to
Sort By:
Pageof 42
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic CancerSeyed Pairawan, Kenneth R Hess, Filip Janku, et al.JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.Nature Medicine|August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trialVivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid CancersRazelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.Cancers|May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/MyxofibrosarcomaAnthony P Conley, Wei-Lien Wang, John A Livingston, et al.Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2022
Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II TrialAlexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.Pageof 42